glycerol has been researched along with Cachexia in 16 studies
Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.
Cachexia: General ill health, malnutrition, and weight loss, usually associated with chronic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aims of the present study were to measure the satiety neuropeptide cholecystokinin (CCK) in humans at terrestrial high altitude to investigate its possible role in the pathophysiology of anorexia, cachexia, and acute mountain sickness (AMS)." | 7.70 | Elevated plasma cholecystokinin at high altitude: metabolic implications for the anorexia of acute mountain sickness. ( Bailey, DM; Calam, J; Davies, B; Jordinson, M; Milledge, JS; Richards, M; Williams, SR, 2000) |
| "We investigated the effect of chronic supplementation with shark liver oil (SLO), an antitumor supplement source of n-3 fatty acids and 1-O-alkylglycerols, alone and combined with coconut fat (CF), a source of saturated fatty acids, on Walker 256 tumor growth and cachexia." | 3.77 | Chronic supplementation with shark liver oil for reducing tumor growth and cachexia in walker 256 tumor-bearing rats. ( de Brito Belo, SR; de Brito, GA; Fernandes, LC; Franzói, AM; Iagher, F; Muehlmann, LA; Muritiba, AL; Naliwaiko, K; Steffani, JA; Yamazaki, RK, 2011) |
| "The aims of the present study were to measure the satiety neuropeptide cholecystokinin (CCK) in humans at terrestrial high altitude to investigate its possible role in the pathophysiology of anorexia, cachexia, and acute mountain sickness (AMS)." | 3.70 | Elevated plasma cholecystokinin at high altitude: metabolic implications for the anorexia of acute mountain sickness. ( Bailey, DM; Calam, J; Davies, B; Jordinson, M; Milledge, JS; Richards, M; Williams, SR, 2000) |
| "Increased energy expenditure in cancer cachexia may be associated with increased postprandial glycogen synthesis via an indirect pathway involving gluconeogenesis." | 3.69 | Effect of acute acipimox administration on the rates of lipid and glycogen synthesis in cachectic tumor-bearing rats. ( Emery, PW; Obeid, OA, 1997) |
| "A mouse model of cancer cachexia was established where cancer exosomes were injected intravenously." | 1.91 | Breast cancer cell-derived exosome-delivered microRNA-155 targets UBQLN1 in adipocytes and facilitates cancer cachexia-related fat loss. ( Li, C; Li, Z; Sun, K; Sun, S; Wang, Z; Yao, F, 2023) |
| "Cachexia is a multifactorial wasting syndrome most common in patients with cancer that is characterized by the uncontrolled loss of adipose and muscle mass." | 1.37 | Adipose triglyceride lipase contributes to cancer-associated cachexia. ( Das, SK; Diwoky, C; Eder, S; Gorkiewicz, G; Guertl, B; Haemmerle, G; Hoefler, G; Kumari, P; Schauer, S; Tamilarasan, KP; Temmel, H; Trauner, M; Vesely, P; Zechner, R; Zimmermann, R, 2011) |
| "Eight malnourished cancer and 10 non-cancer patients (11% weight loss) were compared to seven well-nourished and weight-stable patients." | 1.28 | Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer. ( Drott, C; Lundholm, K; Persson, H, 1989) |
| "While malnutrition attending cancer cachexia may be associated with variable losses of body fat, lipid metabolism has been only minimally studied." | 1.27 | Cancer cachexia and the rate of whole body lipolysis in man. ( Brennan, MF; Horowitz, GD; Jeevanandam, M; Lowry, SF, 1986) |
| "Glycerol was infused intravenously at three different rates (200, 400, and 800 mumol/hr/kg body weight) after an overnight fast." | 1.27 | Glycerol dynamics in weight-losing cancer patients. ( Bennegárd, K; Edén, E; Edström, S; Lindmark, L; Lundholm, K, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chiu, HC | 3 |
| Yang, RS | 3 |
| Weng, TI | 3 |
| Chiu, CY | 3 |
| Lan, KC | 3 |
| Liu, SH | 3 |
| Sun, S | 2 |
| Wang, Z | 1 |
| Yao, F | 1 |
| Sun, K | 1 |
| Li, Z | 1 |
| Li, C | 1 |
| Szabó, T | 1 |
| Postrach, E | 1 |
| Mähler, A | 1 |
| Kung, T | 1 |
| Turhan, G | 1 |
| von Haehling, S | 1 |
| Anker, SD | 1 |
| Boschmann, M | 1 |
| Doehner, W | 1 |
| Ebadi, M | 1 |
| Mazurak, VC | 1 |
| Das, SK | 1 |
| Eder, S | 1 |
| Schauer, S | 1 |
| Diwoky, C | 1 |
| Temmel, H | 1 |
| Guertl, B | 1 |
| Gorkiewicz, G | 1 |
| Tamilarasan, KP | 1 |
| Kumari, P | 1 |
| Trauner, M | 1 |
| Zimmermann, R | 1 |
| Vesely, P | 1 |
| Haemmerle, G | 1 |
| Zechner, R | 1 |
| Hoefler, G | 1 |
| Rydén, M | 1 |
| Agustsson, T | 1 |
| Andersson, J | 1 |
| Bolinder, J | 1 |
| Toft, E | 1 |
| Arner, P | 1 |
| Iagher, F | 1 |
| de Brito Belo, SR | 1 |
| Naliwaiko, K | 1 |
| Franzói, AM | 1 |
| de Brito, GA | 1 |
| Yamazaki, RK | 1 |
| Muritiba, AL | 1 |
| Muehlmann, LA | 1 |
| Steffani, JA | 1 |
| Fernandes, LC | 1 |
| Cassolla, P | 1 |
| Moreira, CC | 1 |
| Liboni, TF | 1 |
| Zaia, CT | 1 |
| Borba-Murad, GR | 1 |
| Bazotte, RB | 1 |
| de Souza, HM | 1 |
| Hajjaji, N | 1 |
| Couet, C | 1 |
| Besson, P | 1 |
| Bougnoux, P | 1 |
| Obeid, OA | 1 |
| Emery, PW | 1 |
| Bailey, DM | 1 |
| Davies, B | 1 |
| Milledge, JS | 1 |
| Richards, M | 1 |
| Williams, SR | 1 |
| Jordinson, M | 1 |
| Calam, J | 1 |
| Klein, S | 1 |
| Wolfe, RR | 1 |
| Drott, C | 1 |
| Persson, H | 1 |
| Lundholm, K | 2 |
| Legaspi, A | 1 |
| Jeevanandam, M | 2 |
| Starnes, HF | 1 |
| Brennan, MF | 2 |
| Horowitz, GD | 1 |
| Lowry, SF | 1 |
| Edén, E | 1 |
| Edström, S | 1 |
| Bennegárd, K | 1 |
| Lindmark, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Biochemical and Functional Biomarkers of Cachexia in Cancer Patients[NCT03191955] | 120 participants (Anticipated) | Observational | 2015-11-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for glycerol and Cachexia
| Article | Year |
|---|---|
Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia.
Topics: Adipokines; Adipose Tissue; Biomarkers; Cachexia; Carrier Proteins; Cytokines; Glycerol; Glycoprotei | 2015 |
15 other studies available for glycerol and Cachexia
| Article | Year |
|---|---|
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
A ubiquitous endocrine disruptor tributyltin induces muscle wasting and retards muscle regeneration.
Topics: Aged; Animals; Cachexia; Diabetes Mellitus, Type 2; Endocrine Disruptors; Glycerol; Humans; Mice; Mu | 2023 |
Breast cancer cell-derived exosome-delivered microRNA-155 targets UBQLN1 in adipocytes and facilitates cancer cachexia-related fat loss.
Topics: Adaptor Proteins, Signal Transducing; Adipocytes; Animals; Autophagy-Related Proteins; Cachexia; Exo | 2023 |
Increased catabolic activity in adipose tissue of patients with chronic heart failure.
Topics: Adipose Tissue; Adult; Aged; Atrial Natriuretic Factor; Blood Glucose; Cachexia; Case-Control Studie | 2013 |
Adipose triglyceride lipase contributes to cancer-associated cachexia.
Topics: Adipose Tissue, White; Animals; Blood Glucose; Body Mass Index; Body Weight; Cachexia; Cytokines; Fa | 2011 |
Adipose zinc-α2-glycoprotein is a catabolic marker in cancer and noncancerous states.
Topics: Adipocytes; Adipose Tissue, White; Adult; Aged; Biomarkers; Biomarkers, Tumor; Body Mass Index; Cach | 2012 |
Chronic supplementation with shark liver oil for reducing tumor growth and cachexia in walker 256 tumor-bearing rats.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Bod | 2011 |
Changes in blood metabolic parameters during the development of Walker-256 tumour-induced cachexia in rats are not caused by decreased food intake.
Topics: Animals; Anorexia; Cachexia; Carcinoma 256, Walker; Cholesterol; Fatty Acids, Nonesterified; Glycero | 2012 |
DHA effect on chemotherapy-induced body weight loss: an exploratory study in a rodent model of mammary tumors.
Topics: Adipose Tissue; Animals; Cachexia; Diet; Disease Models, Animal; Docosahexaenoic Acids; Doxorubicin; | 2012 |
Effect of acute acipimox administration on the rates of lipid and glycogen synthesis in cachectic tumor-bearing rats.
Topics: Animals; Blood Glucose; Cachexia; Gluconeogenesis; Glucose; Glycerol; Glycogen; Hypolipidemic Agents | 1997 |
Elevated plasma cholecystokinin at high altitude: metabolic implications for the anorexia of acute mountain sickness.
Topics: Adult; Altitude Sickness; Analysis of Variance; Anorexia; Anthropometry; Appetite; Blood Glucose; Ca | 2000 |
Whole-body lipolysis and triglyceride-fatty acid cycling in cachectic patients with esophageal cancer.
Topics: Adult; Aged; Cachexia; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fatty Acids; Female; Glycerol | 1990 |
Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer.
Topics: Aged; Blood Pressure; Cachexia; Energy Metabolism; Epinephrine; Fatty Acids, Nonesterified; Female; | 1989 |
Whole body lipid and energy metabolism in the cancer patient.
Topics: Adult; Aged; Cachexia; Energy Metabolism; Esterification; Fatty Acids, Nonesterified; Female; Glycer | 1987 |
Cancer cachexia and the rate of whole body lipolysis in man.
Topics: Adult; Aged; Cachexia; Fatty Acids, Nonesterified; Female; Glycerol; Humans; Lipid Metabolism; Lipol | 1986 |
Glycerol dynamics in weight-losing cancer patients.
Topics: Aged; Body Weight; Breast Neoplasms; Cachexia; Carcinoma; Female; Gastrointestinal Neoplasms; Glycer | 1985 |